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cancer classification algorithms, instead of the original expression values, and we showed that the classification accuracy
was consistently improved across different datasets and classification algorithms. We validated the proposed approach
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Introduction
The use of DNA microarrays has resulted in the identification
and monitoring of numerous cancer marker genes. These genes
have been widely used to differentiate not only cancerous tissue
samples from normal healthy ones, but also between different sub-
types of cancer [1–3]. From a diagnostic point of view, it is
important to correctly identify cancerous tissue so that the most
appropriate treatment can be given as early as possible.
Numerous classifiers have been proposed and evaluated for
their comparative accuracy in correctly identifying cancer tumors
[4–7]. The most prominent of these classifiers are PAM [8], SVM
[9,10], k-NN [11], DT [12], Top Scoring Pair (TSP) [13], and k-
Top Scoring Pair (k-TSP) [6]. The results from these studies
indicate that there is no single classifier that has the highest
accuracy for all the microarray expression datasets. In this paper,
we introduce a novel method that uses gene pairs to improve the
overall accuracy of the existing classification methods without
altering the underlying algorithms.
Recent research has revealed that biomolecular pathways
may be stronger biomarkers for cancer, as compared to the
deregulation of individual genes [14]. The deregulation of a
different subset of genes, associated with the same pathway, may
result in the deregulation of the pathway. Inspecting gene
combinations may thus be more effective for cancer classification
as compared to independently inspecting individual genes.
Motivated by that, the proposed method uses the information
derived from the gene pair combinations, instead of the original
expression values of the genes. We use the derived information as
the input to the existing classification methods. We show that these
gene pair combinations, called doublets, consistently improve the
classification accuracy of the existing classification algorithms.
The significance of the proposed method is that without
changing the underlying classification algorithms we can signifi-
cantly improve the performance of the algorithms by simply
constructing doublets and by using them as input, instead of the
raw gene expression values. The doublets can be constructed in
various ways. In this paper, we experimented with three different
types of doublets: sumdiff, mul and sign doublets. The sumdiff
doublets are constructed by taking the sum and difference of all
pairs of the gene expression vectors such that a doublet is
represented as a vector sum or difference of two gene vectors. The
mul doublets are similarly constructed by taking multiplication, and
the sign doublets are constructed by taking the signs of the
differences of the two gene vectors. Refer to the ‘‘Materials and
Methods’’ section for more details.
Results
LOOCV (Leave One Out Cross Validation) was conducted to measure
the accuracy of doublet-based classification. To test a sample, all
the samples, but the tested one, are used to compute the t{scores
of genes, and the genes are arranged in accordance with the
descending absolute values of the scores. The formula used to
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C2 represent the
variances; and NC1,NC2 represent the number of samples for the
two classes C1 and C2, respectively.
We then select the top 0.2%, 0.4%, 0.6%, 0.8%, 1%, 2%, 4%,
10% of the total number of genes in the dataset for making
doublets. We further prune the doublets so that no gene appears
more than once in the final set of doublets. The algorithm we use
to formulate these unique doublets from the original microarray
expression dataset is outlined as below.
Input: Gene Expression Matrix Q with N genes and M samples,
class vector y for the M samples and T for the number of the
genes required for analysis.
Output: Unique doublets
1. Compute t-scores for matrix Q using class vector y.
2. Make an ordered list H of all the genes gi, in decreasing
value of their absolute t-score.
3. Take the top T genes from the ordered list H, and extract
their expression values from Q. The new expression
matrix Q’ has T rows and M columns.
4. Make doublets from Q’ to get a new matrix Q’’,
with T(T{1) rows and M columns.
5. Compute t-scores for matrix Q’’ using class vector y.
6. Make an ordered list V of all the doublets gigp in Q’’,i n
decreasing value of their absolute t-score.
7. Initialize w as an empty list.
8. forall doublets gigp in V do (in decreasing absolute t-score
order); If neither of the genes in the doublet gigp is in w,
then add doublet gigp to w
9. Return w
The accuracy of the original algorithms is measured using all
the raw expression values of the genes as input. We shall refer to
the accuracy of the original algorithm, for example for PAM, as
PAM, and the accuracy obtained using sumdiff/mul/sign doublets as
input to PAM as sumdiff/mul/sign-PAM, respectively. Figure 1
compares the accuracy of the standard PAM classifier to that of
sumdiff/mul/sign-PAM, obtained by taking the top n% genes, for
the nine datasets listed in Table 1. It can be seen that even taking a
small percentage of the top genes and making doublets could
improve the performance of PAM. The sumdiff/mul/sign-PAM
classifier outperforms the standard PAM classifier in many
datasets.
For the two datasets, CNS and DLBCL, this gain is substantial.
For example, with sign-PAM using the top 2% genes, the accuracy
has increased from 82.4% to 91.2% for the CNS dataset; and for
the DLBCL dataset, the accuracy has increased from 85.5% to
97.4%. The average accuracy of the PAM classifier for the nine
datasets has increased from 88.7% to 90.6%, 89.3% and 91.7%
with sumdiff, mul and sign-PAM with top 2% genes, respectively.
We can make two observations from this result. Only a small
number of the top genes are required to achieve improvements
and that the improvements are quite consistent across the datasets.
In order to show whether or not these observations are still valid
for other classification methods, we performed the same
experiments using different classification methods including the
DT, NB, SVM and k-NN classifiers.
Figure 2 shows the comparison results with DT. The accuracy
of DT was consistently improved across the nine datasets. In some
cases, the improvements were significant. For example, sumdiff-DT
improved the accuracy of DT from 64.8% to 77.3% in the Pros.2
dataset using the top 4% genes; from 73.6% to 93.1% in the
Leukemia dataset with only the top 0.2% genes; and from 80.5%
to 98.7% in the DLBCL dataset with only the top 0.2% genes.
Similarly, mul-DT improved the accuracy of DT from 64.8% to
84.1% in the Pros.2 dataset using the top 0.4% genes; from 84.9%
to 100% in the Pros.3 dataset with the top 0.4% genes; and from
80.5% to 97.4% in the DLBCL dataset with the top 1% genes.
Finally, sign-DT improved the accuracy of DT from 84.9% to
97.0% in the Pros.3 dataset using the top 0.2% genes; from 73.6%
to 95.8% in the Leukemia dataset with the top 0.6% genes; and
from 77.4% to 93.6% in the Colon dataset with the top 0.6%
genes. On average, over the nine datasets, the accuracy of DT was
improved from 78.9% to 85.2%, 84.2% and 89.1% using sumdiff,
mul and sign doublets with the top 0.8% genes, respectively.
Similarly for NB, the accuracy was significantly improved with
sumdiff and mul doublets. The result is shown in Figure 3. One
interesting observation we made is that for NB the sign doublets
have consistently performed worse than the others independent of
the number of the top genes used for doublet generation. This is
because the sign doublets transform the expression values into
binary variables indicating the order of expression level between
the genes in the gene pairs and the transformed binary values do
not retain enough information to compute the class probability
used for classification. Thus, the sign doublets are not suitable for
the NB classifiers. Nonetheless, the performance gains with sumdiff
and mul doublets were substantial. In the Pros.1 dataset, both
sumdiff/mul-NB improved the accuracy from 62.8% to 91.2% with
the top 0.2% genes; in the Colon dataset, the accuracy was
improved from 56.5% to 87.1% and 88.7% with the top 1%
genes, respectively. Finally, in the DLBCL dataset, the accuracy
was improved from 80.5% to 96.1% and 92.2% with the top 0.2%
genes, respectively. On average, the accuracy was improved from
81% to 90.7% and 89.5% with sumdiff and mul doublets with the
top 0.2% genes, respectively.
SVM is known to be one of the most robust classifiers in many
domains. Although its performance was compelling by itself, we
observed that in some cases our doublet approach improved its
performance significantly. The result is shown in Figure 4. In the
Colon dataset, the performance gain was most striking. The
accuracy was improved from 82.3% to 87.1%, 87.1% and 93.6%
with sumdiff/mul/sign doublets with the top 1% genes, respectively.
In the Pros.2 dataset, the accuracy was improved from 76.1% to
80.7%, 84.1% and 85.2% with the top 8%, 0.2% and 1% genes,
respectively. On average, the accuracy was improved from 91.2%
to 92%, 91.9%, and 89.4% with sumdiff/mul/sign doublets with the
top 4% genes, respectively.
Lastly, for k-NN, the same was observed, as is shown in Figure 5.
For k-NN, the performance gain was substantial in almost all
datasets. For example, in the Leukemia dataset, the accuracy was
improved from 84.7% to 98.6%, 98.6%, and 100% with sumdiff/
mul/sign doublets with the top 2%, 0.8% and 0.2% genes,
respectively. On average, the accuracy was improved from 84.3%
to 91%, 90.1% and 90.7% with sumdiff/mul/sign doublets with the
top 4% genes, respectively.
Other than the sign doublets in the NB classifier, use of three
doublets led to improved performance of the baseline classifiers.
The baseline classifiers’ average accuracy rates over the nine
datasets ranged from 79% to 91% (i.e., DT=79%, kNN=84%,
Improving Cancer Classificat
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their average rates with doublets hovered at a higher range, or
from 89% to 92% (i.e., sign-DT=89%, sumdiff-kNN=91%,
sumdiff-NB=89%, sumdiff-SVM=92%, and mul-PAM=90%; all
the figures with top 4% genes). The baseline classifiers showed a
substantial performance difference among them. When it comes to
doublets, however, the difference was minimized and the
performance was improved. All of the three doublet types almost
equally contributed to performance enhancement across various
datasets (except the sign doublets in the NB). The sumdiff/mul/sign
doublets with the top 4% genes marked average accuracies over
the five classifiers of 88.7% (std. 3.4), 88.5% (std. 3.8), and 85.4%
(std. 9.9), respectively. The sumdiff doublets demonstrated a slightly
better performance than the others did. This result is possibly
attributable to the following fact: The sumdiff doublets capture both
of the upwards and downwards relations (i.e., up-up, down-down,
and up-down) and of the order relations of the expression values of
each gene pair. On the contrary, the mul doublets capture the
Figure 1. The accuracy of sumdiff/mul/sign-PAM for the top n% genes compared with the PAM accuracy for each of the nine datasets.
doi:10.1371/journal.pone.0014305.g001
Table 1. The microarray datasets used for classification.
Dataset Platform Total Total Reference
Genes (N) Samples (M)
Colon cDNA 2000 62 Alon [23]
Leukemia Affy 7129 72 Golub [24]
CNS Affy 7129 34 Pomeroy [25]
DLBCL Affy 7129 77 Shipp [26]
Lung Affy 12533 181 Gordon [27]
Prostate1 Affy 12600 102 Singh [28]
Prostate2 Affy 12625 88 Stuart [29]
Prostate3 Affy 12626 33 Welsh [30]
GCM Affy 16063 280 Ramaswamy [31]
doi:10.1371/journal.pone.0014305.t001
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the Materials section for more details.)
Discussion
A recent study suggested that the pathway level deregulation is
more important to carcinogenesis than the deregulation of
individual genes [14]. A pathway is typically deregulated by the
deregulation of more than one gene that is associated with that
pathway. This supports our motivation to use doublets as features
for classification, as the doublets could capture potentially more
information about the pathway level deregulation than the
individual genes. In this study, however, the doublets were pooled
from diverse pathways; namely, not limited to those of the gene
pairs belonging to the same pathways. By allowing all possible
gene combinations, we attempted to capture not only the direct
intra-pathway interactions, but also some of the potential indirect
inter-pathway associations. We plan to pursue in our future work,
the cases where only the intra-pathway doublets are used.
A number of independent studies have attested to the
effectiveness of combining gene pairs. Zhou and her colleagues
have introduced a technique called second-order correlation analysis in
which the pair-wise correlations of genes are utilized for the
functional classification of genes [15]. Their approach operates, as
follows: First computed are all pair-wise correlations of genes
within each dataset (1st-order correlations); then, the correlation
patterns are analyzed across multiple datasets (2nd-order correla-
tions). Selection is made of the gene pairs that show high
correlations in multiple datasets, and the selected form doublets. A
doublet is represented as a vector such that its dimension and
value, respectively, correspond to a dataset and to the correlation
value of the gene pair in the corresponding dataset. The doublets
Figure 2. The accuracy of sumdiff/mul/sign-DT for the top n% genes compared with the DT accuracy for each of the nine datasets.
doi:10.1371/journal.pone.0014305.g002
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doublets clustered together are considered to share similar
functions, because they are turned-on and off collectively across
datasets.
We also have developed microarray data integration techniques
that exploit inter-gene relations, such as correlation signature [16] and
signature cube [17]. The correlation signature projects heterogeneous
microarray expression data onto a coherent information space
where a gene is represented by the vector of its correlations against
a series of landmark genes. If the same set of landmarks is used,
heterogeneous microarray datasets, which could not have been
directly combined, can be integrated, because the correlation
signatures of the genes have compatible dimensions. The signature
cube generalizes the principles of the correlation signature by
providing a heterogeneous microarray data mining framework
where data are represented in relative terms (i.e., inter-gene
relations). Thus, mining algorithm is coherently applicable all
across datasets. Besides the microarray data integration, we also
have applied the principle to the clustering problem and have
introduced a novel clustering framework, SignatureClust [18].
SignatureClust clusters microarray data after projecting it into a
signature space defined by a set of landmark genes chosen by the
user, allowing biologists to get different perspectives of the same
underlying data simply by changing the landmark genes.
It also has been proved that the inter-gene information is useful
for cancer classification purposes. The k-TSP exploits changes in
the expression levels of gene pairs in order to improve the
classification accuracy [6]. The k-TSP classifier uses gene pairs
that are similar to our sign doublets. The k-TSP classifier identifies
the gene pairs whose expression orders are consistently reversed
across the classes; i.e., if gi§gj in most of the control samples and
givgj in most of the cancer samples, then the k-TSP classifier
Figure 3. The accuracy of sumdiff/mul/sign-NB for the top n% genes compared with the NB accuracy for each of the nine datasets.
doi:10.1371/journal.pone.0014305.g003
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The k-TSP classifier finds the top-k pairs, referred to as TSP (Top
Scoring Pairs), and it uses them to determine the classes. The k-
TSP classifier combines the prediction of each TSP using the
unweighted majority voting to determine the final class of a
sample. Recently, the k-TSP algorithm has also been used to
improve the classification accuracy of the SVM classifier [19].
Our method is different from the k-TSP classifier in three
important aspects. First, k-TSP is designed to work with only one
type of gene pairing (similar to our sign doublets), whereas our
method is not limited to specific types of pairing. In this paper, we
have defined three doublets, i.e., sumdiff, mul and sign, but various
other doublets can also be used with the proposed framework.
Second, our method uses existing well established classifiers
instead of devising new classification models. This was made
possible because our method separates the gene pairing step (i.e.,
feature extraction step) from the classification model construction.
Lastly, the k-TSP classifier uses frequency as a metric to assign
score to their gene pairs, whereas we use reliable t-scores. Table 2
summarizes the accuracy results of the doublets and the baseline
classifiers, as well as the accuracy of TSP and k-TSP. TSP refers to
the case where only the single most influential TSP was used for
classification. The TSP and k-TSP classifiers reported a robust
performance, outperforming most of the baseline classifiers. Still,
the two classifiers fall short for the purpose of our study. This study
is significant in that it was demonstrated that a simple doublet-
based feature extraction method remarkably improves the
accuracy of conventional classifiers all the way up to the level of
specialized classification algorithms such as TSP and k-TSP.
The top 15 doublets and their associated KEGG pathways for
the CNS dataset are shown in Table 3. One possible explanation
on why the doublet accuracy is higher than those of the baseline
Figure 4. The accuracy of sumdiff/mul/sign-SVM for the top n% genes compared with the SVM accuracy for each of the nine datasets.
doi:10.1371/journal.pone.0014305.g004
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of the doublet are somehow interlocked with each other, and
therefore form a more robust biomarker compared to each of the
pathways taken individually. However, a more robust investigation
is required before any hypothesis can be validated. In our future
work, we intend to conduct a systematic analysis of these top
doublets, their associated pathways and their possible links to
cancer.
We have shown that combining the expression data from gene
pairs increases the accuracy of classifiers. We also have shown that
increasing the number of genes for making doublets does not
necessarily result in a commensurate increase in accuracy. This is
significant because we can get a very high accuracy even though
we use a very small subset of the total number of genes. Thus, the
computational complexity of computing doublets, which can
potentially be quadratic to the total number of genes in the
dataset, is not critical since only a very small subset of the genes is
used.
The genes comprising the top doublets also provide easily
interpretable results, as compared to other methods like SVM.
Although SVM may provide a higher accuracy than others, it is
essentially a black box and no insight can be gained regarding
biomarker genes. Doublets, on the other hand, are easily
interpretable. Doublets identify which genes and which gene pairs
can serve as biomarkers for tumor classification.
In the future, we plan to analyze these doublets across datasets
and cancer types to select more robust cancer biomarker gene
pairs. Especially, we will investigate how the individual doublets
map to real genes’ relations, such as suppression or stimulation,
and how the relations function with regard to the carcinogenesis. It
Figure 5. The accuracy of sumdiff/mul/sign-k-NN for the top n% genes compared with the k-NN accuracy for each of the nine
datasets.
doi:10.1371/journal.pone.0014305.g005
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classifying multi-class cancer datasets.
Conclusion
The contribution of this paper is twofold. First, it has introduced
doublets, a novel method to combine expression data from gene
pairs. Gene pairs are more robust biomarkers as compared to
individual genes, perhaps reflecting the fact that genes are
interacting to perform a molecular function and the deregulation
of the genes in the interaction, rather than independent genes,
may be responsible for deregulating the critical pathways. Second,
we have combined doublets with conventional classifiers to
produce classifiers whose accuracy is greater than that of the
original ones. We validated the framework using five well-known
classifiers including PAM, DT, NB, SVM, and kNN. We showed
that doublets can be easily incorporated into the existing classifiers
without having to change the underlying algorithms, and that
using doublets can consistently improve the classification accuracy
of the original algorithms across different datasets.
Materials and Methods
Gene Doublets
Let there be N genes fg1,...,gNg in a tissue sample, and let
there be M such tissue samples fx1,...,xMg. The cancer dataset
could then be represented as matrix Q of dimension N|M.
Then, gij would denote the expression value of the i-th gene,
i[f1,...,Ng in the j-th sample, j[f1,...,Mg. The gene vector gi
= fgi1,...,giMg would denote the expression value of the i-th
gene across the M tissue samples, and the column vector xj =
fg1j,...,gNjg would represent the j-th tissue sample across the N
genes. The class labels for the tissue samples are represented by
vector y = fy1,...,yMg, where yj[fC1,...,CKg, the set of all
class labels. For our binary classification problem, K~2, where C1
denotes cancerous and C2 denotes normal tissue samples.
For each pair of genes i,p[f1,...,Ng,1ƒivpƒN in a dataset,
we define a positive doublet vector and a negative doublet vector
as
gigpz~fgi1zgp1,gi2zgp2,...,giMzgpMgð 2Þ
gigp{~fgi1{gp1,gi2{gp2,...,giM{gpMgð 3Þ
Thus, for our dataset with N genes, we have N(N{1)=2 positive
doublets and N(N{1)=2 negative doublets, and our original
microarray dataset of dimension N|M is transformed into an
N(N{1)|M matrix. Each row in this new matrix represents a
doublet (positive or negative). We denote this matrix as S, with
dimension D|M, where D~N(N{1); thus, the defined
doublets are known as sumdiff doublets. In another variation of
making doublets, we define the mul doublets as:
gigp|~fgi1|gp1,gi2|gp2,...,giM|gpMgð 4Þ
and sign doublets as:
Table 2. LOOCV accuracy of the classifiers for the binary class expression datasets.
Method Leukemia CNS DLBCL Colon Pros.1 Pros.2 Pros.3 Lung GCM Avg.
TSP* 93.80 77.90 98.10 91.10 95.10 67.60 97.00 98.30 75.40 88.26
k-TSP* 95.83 97.10 97.40 90.30 91.18 75.00 97.00 98.90 85.40 92.01
DT 73.61 67.65 80.52 77.42 87.25 64.77 84.85 96.13 77.86 78.90
sumdiff-DT
{ 91.67 70.59 97.40 64.52 82.35 77.27 87.88 95.03 81.43 83.13
mul-DT
{ 84.72 55.88 97.40 79.03 86.27 69.32 90.91 92.27 83.21 82.11
sign-DT
{ 93.06 82.35 97.40 88.71 86.27 73.86 96.97 98.34 85.00 89.11
NB 100.00 82.35 80.52 56.45 62.75 73.86 90.91 97.79 84.29 80.99
sumdiff-NB
{ 98.61 82.35 92.21 87.10 82.35 76.14 96.97 99.45 81.43 88.51
mul-NB
{ 97.22 79.41 89.61 85.48 85.29 75.00 100.00 100.00 82.50 88.28
sign-NB
{ 65.28 73.53 75.32 64.52 50.98 56.82 72.73 82.87 67.86 67.77
k-NN 84.72 82.35 89.61 74.19 74.51 73.86 93.94 98.34 86.79 84.26
sumdiff-k-NN
{ 98.61 85.29 94.81 83.87 91.18 76.14 96.97 99.45 92.86 91.02
mul-k-NN
{ 97.22 85.29 93.51 80.65 85.29 77.27 100.00 100.00 91.79 90.11
sign-k-NN
{ 97.22 85.29 96.10 82.26 88.24 76.14 100.00 99.45 91.79 90.72
SVM 98.61 82.35 97.40 82.26 91.18 76.14 100.00 99.45 93.21 91.18
sumdiff-SVM
{ 98.61 82.35 96.10 88.71 93.14 78.41 100.00 99.45 91.07 91.98
mul-SVM
{ 97.22 88.24 96.10 87.10 88.24 79.55 100.00 99.45 91.07 91.89
sign-SVM
{ 97.22 79.41 97.40 79.03 89.22 75.00 100.00 99.45 87.5 89.36
PAM 94.03 82.35 85.45 89.52 90.89 81.25 94.24 97.90 82.32 88.66
sumdiff-PAM
{ 95.83 79.41 87.01 87.10 93.14 77.27 96.97 98.34 83.57 88.74
mul-PAM
{ 95.83 85.29 92.21 90.32 92.16 79.55 93.94 98.90 82.86 90.12
sign-PAM
{ 95.83 85.29 94.81 88.71 90.20 76.14 100.00 98.9 81.07 90.11
*Results obtained in [6]
{Results from taking the top 4% of genes for making unique doublets.
doi:10.1371/journal.pone.0014305.t002
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Doublet No. Probe 1 Gene 1 KEGG 1 Probe 2 Gene 2 KEGG 2
1 U40317_s_at PTPRS Unknown U27459_at ORC2L Cell cycle
2 J00212_f_at IFNA21 Cytokine-cytokine receptor interaction U33920_at SEMA3F Axon guidance
Regulation of autophagy
Antigen processing and presentation
Toll-like receptor signaling pathway
Jak-STAT signaling pathway
Natural killer cell mediated cytotoicity
Autoimmune thyroid disease
3 D50924_at DHX34 Unknown X04707_at THRB Neuroactive ligand-
receptor interaction
4 U31215_s_at GRM1 Calcium signaling pathway M64929_at PPP2R2A Tight junction
Neuroactive ligand-receptor interaction
Gap junction
Long-term potentiation
Long-term depression
5 U52828_s_at CTNND2 Unknown U33267_at GLRB Neuroactive ligand-
receptor interaction
6 D50582_at KCNJ11 Type II diabetes mellitus Y10204_at Unknown Unknown
7 U83600_at TNFRSF25 Cytokine-cytokine receptor interaction HG2260-HT2349_s_at Unknown Unknown
8 S77835_s_at IL2 Cytokine-cytokine receptor interaction M60858_rna1_at NCL Pathogenic Escherichia
coli infection - EHEC
Jak-STAT signaling pathway Pathogenic Escherichia
coli infection - EPEC
T cell receptor signaling pathway
Type I diabetes mellitus
Autoimmune thyroid disease
Allograft rejection
Graft-versus-host disease
9 L32179_at AADAC Alkaloid biosynthesis II M14660_at IFIT2 Unknown
10 D50310_at CCNI Unknown L78833_cds2_at RND2 Unknown
11 HG2417-HT2513_at Unknown Unknown U35451_at CBX1 Unknown
12 U03090_at PLA2G5 Glycerophospholipid metabolism M16594_at GSTA2 Glutathione
metabolism
Ether lipid metabolism Metabolism of
enobiotics by
cytochrome P450
Arachidonic acid metabolism Drug metabolism -
cytochrome P450
Linoleic acid metabolism
alpha-Linolenic acid metabolism
MAPK signaling pathway
VEGF signaling pathway
Fc epsilon RI signaling pathway
Long-term depression
GnRH signaling pathway
13 U68536_at ZNF24 Unknown X64728_at CHML Unknown
14 L43964_at PSEN2 Notch signaling pathway X98206_at Unknown Unknown
Alzheimers disease
15 D13118_at ATP5G1 Oxidative phosphorylation U78556_at MTMR11 Unknown
Alzheimers disease
Parkinsons disease
doi:10.1371/journal.pone.0014305.t003
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ð5Þ
The sumdiff doublets capture up-up, down-down (i.e. positive
doublets) and up-down (i.e. negative doublets) relations of the
expression values of gene pairs. Furthermore, the negative
doublets capture the order of expression values between the genes
in the gene pair. Please be noted that the datasets were processed
to have a minimum value of 10 and a maximum of 16,000.
Thereafter, the values were converted through log2. Then, all the
samples were standardized to zero mean and unit variance. The
mul doublets not only capture the up-up, down-down, and up-
down relations of gene pairs, but also amplify the relations through
multiplication. However, the mul doublets do not capture the
expression orders between genes. On the other hand, the sign
doublets capture the inter-gene expression orders alone.
Microarray Data and Classification Methods
The microarray data is taken from several studies, as is shown in
Table 1. These are the same datasets that were used in [6] for
comparing TSP and k-TSP with various classifiers. The micro-
arrays consist of the expression data for the tissues associated with
colon, blood, lung, breast, prostate, and cancer of the central
nervous system. The number of samples and the number of genes
in each study are also shown in Table 1. For the baseline
classifiers, we used the implementations available in Bioconductor
(for PAM) [20] and Weka (for DT, NB, SVM and kNN) [21].
Classification Accuracy
We use the LOOCV (Leave One Out Cross Validation) method to
estimate the classifier accuracy. For each sample xj in the dataset,
we use the rest of the M{1 samples in the dataset to predict the
class of the xj sample. The classification accuracy of each dataset is
the ratio of the number of the correctly classified samples (True
Positives+True Negatives) to the total number of samples (M) in
that dataset.
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